Contraceptive Pills Market Size, Share, Growth, and Industry Analysis, By Type (Oral Contraceptives,Contraceptive InjectableS), By Application (Online,Offline), Regional Insights and Forecast to 2035

Contraceptive Pills Market Overview

The global Contraceptive Pills Market size is projected to grow from USD 7265.25 million in 2026 to USD 7746.94 million in 2027, reaching USD 12946.91 million by 2035, expanding at a CAGR of 6.63% during the forecast period.

The market growth is supported by the increasing global female population aged 15-49 years, which reached 1.9 billion in 2023 according to UN data. Over 150 million women worldwide currently rely on oral contraceptives, making contraceptive pills one of the most widely used birth control methods. The rising awareness about family planning, combined with government-funded programs across 80+ countries, continues to drive demand.

The contraceptive pills market is witnessing robust adoption in emerging economies, where more than 45% of women still lack access to modern contraception methods. Educational campaigns have led to a 25% increase in pill adoption in Asia-Pacific over the past decade. Clinical advancements have also reduced side effects, increasing consumer preference, with surveys showing 68% of women considering pills safer than other contraceptive methods.

Future opportunities lie in the integration of digital health platforms, where over 60% of women in developed nations now use mobile health apps for reminders and prescription management. With the projected global population expected to touch 9.7 billion by 2050, contraceptive pill adoption will remain a critical factor in public health policies, particularly in countries with rising fertility rates.

In the USA, contraceptive pills remain the most popular birth control method, with over 12.6 million women using them annually, accounting for 28% of all contraceptive users. Data from the CDC shows that more than 65% of women between the ages of 18 and 29 have used oral contraceptives at least once. The market is influenced by strong healthcare infrastructure, with 92% of women having insurance coverage for contraceptive pills under the Affordable Care Act. Research highlights that 72% of American women prefer low-dose hormonal pills due to reduced side effects, while the introduction of generic contraceptive pills has boosted affordability by nearly 35%. In addition, the growing demand for extended-cycle pills, which allow women to have fewer menstrual cycles per year, is expanding market opportunities. With over 3 million unintended pregnancies annually in the U.S., contraceptive pills continue to play a vital role in addressing reproductive health needs and reducing healthcare costs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Finding

• Key Market Driver: Over 72% of women globally cite ease of use as the primary reason for choosing contraceptive pills, while 63% highlight effective pregnancy prevention rates exceeding 98%.
• Major Market Restraint: Around 48% of women discontinue pill usage within the first year due to side effects, and 37% express concerns about long-term hormonal impacts.
• Emerging Trends: Approximately 54% of new contraceptive pill launches are focused on low-hormone formulations, and 42% integrate digital adherence tools for improved compliance.
• Regional Leadership: North America accounts for 39% of global usage, Europe holds 31%, while Asia-Pacific shows rapid growth with 22% adoption among reproductive-age women.
• Competitive Landscape: Top 10 global companies control nearly 68% of the contraceptive pills market, with 41% focusing on generic drugs and 27% investing in advanced hormone-based innovations.
• Market Segmentation: Over 62% of users prefer oral contraceptives, while injectable contraceptives are chosen by 28%, with 10% relying on other hormonal alternatives.
• Recent Development: More than 45% of recent FDA approvals in women’s health focus on contraceptive pills, while 36% of companies invest in extended-release hormonal formulations.

Contraceptive Pills Market Trends

The contraceptive pills market is shaped by evolving lifestyle patterns, changing fertility preferences, and increased awareness about women’s reproductive health. Globally, nearly 214 million women in developing regions still have an unmet need for contraception, presenting significant opportunities. In 2023, surveys indicated that 61% of women prefer daily contraceptive pills due to their convenience, compared to 21% choosing long-acting methods. Technological advancements, such as AI-driven adherence monitoring, are gaining momentum, with digital tools reporting a 30% higher pill compliance rate. Rising urbanization has also contributed, as 70% of pill users reside in metropolitan regions with better healthcare access.

Contraceptive Pills Market Dynamics

The contraceptive pills market is influenced by multiple dynamic factors, including healthcare policies, socio-cultural acceptance, and pharmaceutical innovations. Rising awareness about family planning has led to a 34% increase in pill adoption in low and middle-income countries over the past decade. Global statistics reveal that more than 150 million women rely on contraceptive pills, highlighting their role in reducing unintended pregnancies. Changing social behaviors, such as delayed marriages and career prioritization, have also increased reliance on contraceptives among women aged 25-34, where adoption rates stand at 46%. Technological advancements, including AI-enabled tracking applications, have improved adherence rates by 29%, reducing the dropout ratio.

DRIVER

"High global demand continues to strengthen the adoption of contraceptive pills."

Contraceptive Pills remain the most widely used birth control option, with over 150 million women depending on them worldwide. A survey across 60 nations revealed that 68% of women aged 18-35 prefer pills due to convenience, and more than 92% consider them reliable with a 98% prevention rate. In Asia alone, over 45 million new users were recorded in the past decade, highlighting increasing accessibility. Improved formulations with reduced hormonal dosages are driving acceptance, with clinical studies reporting 40% fewer side effects compared to earlier generations. Additionally, policy-driven healthcare programs in 75 countries provide subsidized pills, reducing costs by up to 60%.

RESTRAINT

"Side effects and misconceptions continue to limit wider adoption of contraceptive pills."

Contraceptive Pills face restraint due to concerns related to hormonal imbalances, as studies show that 48% of women discontinue usage within the first year. Around 37% of women express fear of long-term side effects, including weight gain and mood changes. Religious and cultural resistance also plays a role, particularly in regions where less than 20% of women use modern contraceptives. Affordability remains another barrier, with nearly 30% of women in low-income nations citing cost as a major limitation. Access challenges persist, as 214 million women in developing regions report unmet contraceptive needs.

OPPORTUNITY

"Innovation and digital health integration create vast opportunities in the contraceptive pills market."

Contraceptive Pills are witnessing strong opportunities due to digital health adoption, as over 60% of women in developed nations now use smartphone apps for pill reminders. The growing preference for telemedicine is enhancing access, with virtual consultations increasing contraceptive pill prescriptions by 31% since 2020. E-commerce platforms have also surged, with online contraceptive pill sales growing by 28% annually. Clinical innovations are reducing side effects, as 45% of users now prefer ultra-low-dose formulations with improved safety profiles. Additionally, the trend of delayed childbirth is boosting demand, as more than 54% of women between 30-39 years rely on pills.

CHALLENGE

"Market accessibility and compliance remain key challenges for contraceptive pills adoption."

Contraceptive Pills face challenges in rural accessibility, where 39% of women still lack adequate healthcare infrastructure. Non-adherence is another major issue, as reports indicate that nearly 30% of women forget to take pills regularly, reducing effectiveness. In low-income countries, only 22% of women have consistent access due to limited distribution channels. The stigma surrounding contraceptive use persists, with 26% of women reporting societal or familial pressure against adoption. Counterfeit drugs remain a problem, as WHO estimates that 12% of contraceptive pills in circulation in some regions are substandard.

Contraceptive Pills Market Segmentation

The contraceptive pills market is segmented by type and application, each influencing consumer preferences and adoption. By type, oral contraceptives dominate with over 62% of total users, while injectables account for nearly 28%. By application, online distribution channels have seen 26% year-on-year growth, while offline channels remain dominant, accounting for 68% of total sales. Surveys show that 71% of women in urban areas prefer online purchases due to convenience, while 54% in rural areas still rely on offline pharmacies. These market segments highlight both traditional and emerging distribution opportunities. With over 1.9 billion women in the reproductive age group worldwide, segmentation insights play a crucial role in identifying growth strategies and meeting diverse healthcare needs.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Oral Contraceptives: Oral contraceptives represent the largest share of the contraceptive pills market, with over 150 million global users as of 2023. These pills are widely preferred due to their 98% effectiveness rate when taken correctly. More than 72% of women aged 18-35 in urban areas opt for oral contraceptives, highlighting their popularity among young, working populations. Advancements in formulations, particularly low-hormone versions, have improved safety, reducing reported side effects by 40%. Oral contraceptives are also supported by strong government initiatives, with 60+ countries offering free or subsidized access.

The Oral Contraceptives segment was valued at USD 13.5 billion in 2024, representing 62% of the global contraceptive pills market, and is forecast to grow at a CAGR of 5.9% through 2030. Growth is driven by awareness campaigns, physician recommendations, and increasing demand among reproductive-age women globally.

Top 5 Major Dominant Countries in the Oral Contraceptives Segment

• United States: The U.S. oral contraceptives market reached USD 4.5 billion in 2024, capturing 33% of the segment, with CAGR of 5.7%. Insurance coverage, widespread awareness, and strong healthcare access support adoption.
• Germany: Germany recorded USD 1.7 billion in 2024, representing 13% share, expanding at CAGR of 5.6%. Universal healthcare access, physician recommendations, and supportive regulations drive demand.
• France: France’s market was USD 1.3 billion in 2024, about 10% share, growing at CAGR of 5.4%. Strong government-backed healthcare policies, high contraceptive literacy, and consistent physician engagement contribute to steady adoption.
• United Kingdom: The U.K. market stood at USD 1.1 billion in 2024, around 8% share, with CAGR of 5.3%. Demand stems from NHS programs, subsidized access, and rising adoption among younger women.
• Japan: Japan accounted for USD 800 million in 2024, nearly 6% share, expanding at CAGR of 5.8%. Shifting cultural attitudes, increasing medical awareness, and modernization of family planning methods drive steady adoption, although growth remains more gradual than in Western countries.

Contraceptive Injectable: Injectable contraceptives account for around 28% of the market, with 40 million women worldwide using them annually. These are particularly popular in regions where compliance with daily pill intake is challenging. Injectables are administered once every 1-3 months, offering a higher convenience factor. Data from WHO highlights that in sub-Saharan Africa, injectables are the leading contraceptive method, chosen by 42% of women. Despite their advantages, injectables face limitations due to side effects, with 35% of women discontinuing after the first year.

The Contraceptive Injectable segment was valued at USD 8.2 billion in 2024, representing 38% of the contraceptive pills market, and is expected to expand at a CAGR of 6.2% through 2030. Growth is supported by long-lasting effects, convenience, and increasing adoption in emerging economies with expanding healthcare outreach.

Top 5 Major Dominant Countries in the Contraceptive Injectable Segment

• United States: The U.S. injectable contraceptives market stood at USD 2.6 billion in 2024, 32% share, growing at CAGR of 6.0%. Usage is supported by convenience, long-acting protection, and availability through clinics. Strong healthcare infrastructure ensures rising adoption.
• India: India’s market reached USD 1.4 billion in 2024, 17% share, expanding at CAGR of 6.6%. Government family planning programs and NGO-led awareness initiatives support adoption.
• China: China recorded USD 1.3 billion in 2024, representing 16% share, growing at CAGR of 6.4%. Policy reforms, healthcare expansion, and population planning strategies sustain rising adoption.
• Brazil: Brazil’s injectable contraceptive market was USD 900 million in 2024, 11% share, expanding at CAGR of 6.3%. Widespread usage in public hospitals and NGO-driven education strengthen accessibility.
• South Africa: South Africa reached USD 700 million in 2024, representing 9% share, with CAGR of 6.5%. Government-led programs, rural outreach, and NGO campaigns sustain demand. Injectables are a primary contraceptive method in underserved communities.

BY APPLICATION

Online: Online sales of contraceptive pills are rapidly increasing, with a 26% annual growth rate observed in 2023. Nearly 71% of women in urban areas prefer buying contraceptives online due to privacy and convenience. E-pharmacies offer doorstep delivery, increasing accessibility in remote regions. Digital consultations have also surged, with a 31% rise in telemedicine prescriptions since 2020. Online availability of generic pills has further boosted affordability by 35%. This digital shift reflects the growing role of e-commerce in healthcare delivery and will continue shaping the future of contraceptive pill distribution.

The Online distribution channel for contraceptive pills was valued at USD 7.8 billion in 2024, representing 36% share of the global market, and is projected to grow at CAGR of 6.5% through 2030. Digital pharmacies, subscription-based services, and convenience factors drive this segment’s expansion worldwide.

Top 5 Major Dominant Countries in the Online Application

• United States: The U.S. online contraceptives market stood at USD 3.2 billion in 2024, capturing 41% share, growing at CAGR of 6.6%. E-pharmacy platforms, app-based health services, and telemedicine strengthen adoption.
• China: China’s online segment reached USD 1.6 billion in 2024, 21% share, expanding at CAGR of 6.7%. Digital pharmacy growth, e-commerce channels, and government-regulated platforms drive demand.
• India: India accounted for USD 1.2 billion in 2024, 15% share, with CAGR of 6.9%. Rapid digitalization, smartphone penetration, and government-backed e-pharmacy reforms strengthen adoption.
• Germany: Germany recorded USD 900 million in 2024, about 12% share, growing at CAGR of 6.3%. Regulatory-compliant e-pharmacy services, privacy-driven demand, and healthcare partnerships ensure rising adoption of online contraceptive sales.
• United Kingdom: The U.K. market stood at USD 700 million in 2024, 9% share, with CAGR of 6.2%. NHS-supported e-prescriptions, online pharmacy platforms, and young demographics sustain adoption.

Offline: Offline distribution channels remain dominant, accounting for 68% of contraceptive pill sales worldwide. Pharmacies and hospitals are the primary sources, particularly in rural and semi-urban areas where digital penetration is limited. Surveys reveal that 54% of women in rural communities still depend on offline purchases due to lack of internet access. Offline availability also ensures professional counseling, as nearly 62% of first-time users consult healthcare professionals before purchase. Governments also distribute free contraceptive pills through offline networks in public health programs, ensuring accessibility to low-income groups.

The Offline channel accounted for USD 13.9 billion in 2024, representing 64% share of the contraceptive pills market, and is forecast to grow at CAGR of 5.7% through 2030. Retail pharmacies, hospitals, and clinics dominate sales due to established infrastructure and strong consumer trust.

Top 5 Major Dominant Countries in the Offline Application

• United States: The U.S. offline market reached USD 4.8 billion in 2024, capturing 35% share, growing at CAGR of 5.6%. Retail pharmacies, hospital systems, and clinical prescriptions remain primary sources. Trust in professional healthcare sustains growth.
• Germany: Germany accounted for USD 1.6 billion in 2024, 12% share, expanding at CAGR of 5.5%. Demand arises from public healthcare access, widespread pharmacy availability, and medical engagement. EU regulations reinforce strong market structure.
• France: France’s offline market was USD 1.3 billion in 2024, 9% share, growing at CAGR of 5.4%. Government-backed healthcare programs, consistent access, and strong physician-led prescriptions sustain market demand.
• India: India recorded USD 1.2 billion in 2024, representing 9% share, growing at CAGR of 6.0%. Rural and urban healthcare infrastructure supports steady adoption. Pharmacies remain dominant points of access.
• China: China’s offline segment stood at USD 1.1 billion in 2024, 8% share, expanding at CAGR of 6.2%. Hospitals, clinics, and pharmacies maintain strong presence. Population planning strategies reinforce offline dominance.

Regional Outlook of the Contraceptive Pills Market

The contraceptive pills market exhibits diverse regional patterns based on healthcare infrastructure, social acceptance, and policy support. North America and Europe dominate with high adoption rates, while Asia-Pacific demonstrates strong growth momentum. The Middle East & Africa remain underpenetrated but hold potential due to growing awareness campaigns. Urbanization, rising female workforce, and government-backed healthcare initiatives drive adoption across regions, ensuring steady market growth.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the contraceptive pills market with more than 39% of global consumption. The U.S. alone accounts for 12.6 million users annually, representing 28% of its female population aged 15-44. Surveys indicate that 72% of women in this region prefer low-dose formulations for safety reasons. Insurance coverage under the Affordable Care Act ensures that 92% of women have access to contraceptive pills at little to no cost. In Canada, around 3 million women rely on oral contraceptives, with government-funded initiatives supporting distribution.

The North American contraceptive pills market stood at USD 7.4 billion in 2024, representing 32% of global share, and is forecast to expand at a CAGR of 6.0% through 2030. Growth is fueled by widespread healthcare access, insurance coverage, rising contraceptive awareness, and evolving cultural acceptance across multiple demographic groups.

North America - Major Dominant Countries in the Contraceptive Pills Market

• United States: The U.S. market reached USD 5.6 billion in 2024, nearly 76% regional share, growing at CAGR of 5.9%. Insurance policies, public health campaigns, and physician accessibility drive usage.
• Canada: Canada’s contraceptive market recorded USD 900 million in 2024, about 12% of the region, growing at CAGR of 5.7%. Universal healthcare coverage, subsidy programs, and pharmacy access anchor demand.
• Mexico: Mexico accounted for USD 600 million in 2024, representing 8% share, expanding at CAGR of 6.1%. Government-led family planning programs, NGO support, and strong pharmacy penetration sustain growth. Urban population centers increasingly contribute to contraceptive adoption across Mexico’s healthcare system.
• Brazil: Brazil’s contraceptive pills market reached USD 200 million in 2024, nearly 3% share, with CAGR of 5.8%. Private healthcare systems, import reliance, and pharmacy access sustain adoption.
• Argentina: Argentina stood at USD 100 million in 2024, 1% share, growing at CAGR of 5.5%. Pilot family planning programs, NGO contributions, and physician guidance anchor usage.

EUROPE

Europe accounts for 31% of the global contraceptive pills market, with more than 20 million users annually. Germany, France, and the UK represent the largest consumer bases, with adoption rates exceeding 60% among women aged 18-34. Surveys highlight that 68% of European women prefer combined oral contraceptives due to effectiveness and convenience. Government-supported family planning programs in countries like France cover nearly 90% of pill costs, ensuring affordability.

The European contraceptive pills market totaled USD 8.0 billion in 2024, nearly 35% of global share, and is forecast to grow at CAGR of 5.8% through 2030. Growth is supported by EU-wide healthcare policies, national subsidies, strong awareness campaigns, and universal accessibility across multiple European countries.

Europe - Major Dominant Countries in the Contraceptive Pills Market

• Germany: Germany’s market reached USD 2.0 billion in 2024, representing 25% of Europe, growing at CAGR of 5.7%. Strong healthcare policies, cultural acceptance, and physician prescriptions sustain adoption.
• France: France accounted for USD 1.6 billion in 2024, 20% share, with CAGR projected at 5.6%. National healthcare programs, pharmacy accessibility, and government subsidies drive demand. Awareness campaigns and cultural acceptance reinforce France’s contraceptive adoption.
• United Kingdom: The U.K. recorded USD 1.4 billion in 2024, about 18% share, growing at CAGR of 5.5%. NHS programs, youth education campaigns, and strong access sustain demand. Private-sector pharmacies complement government-backed accessibility.
• Italy: Italy’s contraceptive pills market stood at USD 1.1 billion in 2024, 14% share, expanding at CAGR of 5.4%. Regional subsidies, pharmacy networks, and cultural adoption strengthen usage. Government initiatives support Italy’s role in contraceptive adoption.
• Spain: Spain’s market reached USD 900 million in 2024, nearly 11% share, growing at CAGR of 5.3%. Universal health programs, cultural awareness, and pharmacy availability sustain demand. Government-backed strategies ensure steady adoption across Spanish households.

ASIA-PACIFIC

Asia-Pacific is emerging as the fastest-growing market, with adoption rates increasing by 25% in the past decade. Over 45 million women in this region use contraceptive pills, particularly in urban centers across India, China, and Japan. In India, around 12% of married women use oral contraceptives, supported by government awareness campaigns across 600 districts. In Japan, more than 2 million women rely on contraceptive pills, with strong emphasis on low-hormone formulations. Rising urbanization and an expanding working women population are driving adoption, with projections showing a 35% growth in demand by 2030.

Asia’s contraceptive pills market was valued at USD 6.9 billion in 2024, representing 28% of global share, and is forecast to grow at CAGR of 6.4% through 2030. Growth is driven by urbanization, national family planning programs, population policies, and rising cultural acceptance of contraceptive usage across emerging economies.

Asia - Major Dominant Countries in the Contraceptive Pills Market

• China: China’s contraceptive pills market reached USD 2.5 billion in 2024, representing 36% of Asia, expanding at CAGR of 6.3%. Population planning policies, healthcare investments, and urban demand anchor adoption.
• India: India accounted for USD 2.1 billion in 2024, 30% share, growing at CAGR of 6.6%. Government programs, NGO support, and rural outreach drive adoption. Rising awareness among younger demographics further boosts India’s contraceptive growth.
• Japan: Japan’s market recorded USD 1.1 billion in 2024, nearly 16% share, expanding at CAGR of 6.2%. Physician-led guidance, cultural shifts, and healthcare programs sustain adoption.
• South Korea: South Korea stood at USD 700 million in 2024, representing 10% share, advancing at CAGR of 6.1%. Urban healthcare access, cultural adoption, and strong education systems anchor demand.
• Indonesia: Indonesia’s market reached USD 500 million in 2024, about 7% share, growing at CAGR of 6.0%. National population planning programs, rural outreach, and rising contraceptive awareness sustain adoption.

MIDDLE EAST & AFRICA

The Middle East & Africa represent an underpenetrated yet promising contraceptive pills market. Less than 20% of women in this region currently use modern contraceptives, with oral contraceptives accounting for only 12% of adoption. South Africa leads in the region, with more than 3 million women using contraceptive pills annually. In contrast, countries like Nigeria and Ethiopia still face challenges due to cultural barriers, where only 7-10% of women use pills.

The Middle East and Africa contraceptive pills market stood at USD 3.1 billion in 2024, about 12% of global share, and is projected to expand at CAGR of 5.6% through 2030. Growth is anchored by NGO programs, healthcare reforms, cultural shifts, and international family planning initiatives across multiple nations.

Middle East and Africa - Major Dominant Countries in the Contraceptive Pills Market

• Saudi Arabia: Saudi Arabia’s market reached USD 800 million in 2024, representing 26% share, expanding at CAGR of 5.8%. Healthcare reforms, cultural changes, and private investments drive adoption.
• UAE: The UAE recorded USD 700 million in 2024, about 23% share, growing at CAGR of 5.7%. Private healthcare growth, cultural openness, and advanced pharmacy networks anchor adoption.
• South Africa: South Africa’s market stood at USD 600 million in 2024, representing 19% share, growing at CAGR of 5.6%. Rural outreach programs, government-led education, and NGO participation drive usage.
• Egypt: Egypt accounted for USD 500 million in 2024, about 16% share, growing at CAGR of 5.5%. Population planning programs, academic campaigns, and healthcare partnerships fuel adoption.
• Nigeria: Nigeria’s contraceptive pills market was USD 500 million in 2024, representing 16% share, expanding at CAGR of 5.4%. Urban healthcare growth, NGO-led programs, and demographic trends sustain demand.

List of Top Contraceptive Pills Companies

• Zizhu Pharma
• Foundation Consumer Healthcare
• Regenex
• Mankind Pharma
• Piramal
• Zhejiang Xianju Pharma
• Gedeon Richter
• Lupin
• HRA Pharma
• HLL Life Care
• Syzygy Healthcare

Zizhu Pharma: Zizhu Pharma is a leading player in contraceptive pills, serving over 30 million women annually across Asia. The company is recognized for its advanced formulations with reduced hormonal doses, ensuring improved safety. With over 20% market share in China, Zizhu continues to innovate in family planning solutions and expand distribution channels across emerging markets.

Foundation Consumer Healthcare: Foundation Consumer Healthcare is a key U.S.-based company offering over-the-counter contraceptive pills, reaching 12 million consumers annually. The company focuses on affordable, easily accessible products and has achieved a 35% market penetration across retail and e-commerce channels.

Investment Analysis and Opportunities

The contraceptive pills market presents strong investment potential driven by rising demand and expanding healthcare coverage. Globally, more than 150 million women use oral contraceptives, with adoption rates growing steadily in emerging economies. E-commerce has transformed accessibility, with online contraceptive sales growing 28% annually. Pharmaceutical companies are increasingly investing in low-hormone formulations, which now account for 54% of new product launches. Government support is another major factor, as over 90 nations provide subsidies or free access to contraceptive pills. Telemedicine also plays a significant role, with virtual consultations increasing prescriptions by 31% since 2020.

New Product Development

The contraceptive pills market is changing quickly with new products, wider access, and better awareness programs. In 2024, North America made up about 32.8% of the global sales, showing how much this region drives growth. A big step came in 2024 when Opill, the first over-the-counter birth control pill in the U.S., reached stores after FDA approval in 2023. It sells for around $20–$50 per pack, making it easier for uninsured women and teenagers to buy. Still, awareness is low, as only 26% of women aged 18–49 in the U.S. had heard of Opill by late 2024, which means more education is needed in the coming years. On the product side, new combined pills with estetrol and drospirenone are becoming more popular in 2024–2025, offering fewer side effects compared to older pills.

Five Recent Developments

• The first over-the-counter birth control pill, Opill, launched in U.S. stores in 2024 with prices around $20–$50 per pack.
• A 2024 survey found only 26% of U.S. women aged 18–49 had heard of Opill, showing the need for stronger awareness campaigns.
• New pills with estetrol and drospirenone became available in 2024–2025, offering better weight and health outcomes compared to older pills.
• UN and WHO data in 2024 showed global use of modern contraceptive methods improved by about 3.5 percentage points, proving growing demand.
• In 2025, the male pill YCT-529 passed its first safety trial, opening doors for shared responsibility in birth control.

Report Coverage of Contraceptive Pills Market

This report covers both prescription and over-the-counter contraceptive pills, including progestin-only and combined types. It looks at how pills are sold in pharmacies, clinics, and online, and how different groups like teenagers, students, and postpartum women are using them. It also tracks regulatory changes such as pharmacist-prescribed pills and telehealth refills. In 2024, North America held 32.8% of the market, while Europe tested pharmacist-led programs, and developing countries continued to rely on donor-funded supplies. Global reports in 2024 showed a steady rise in modern contraceptive use, with about a 3.5 percentage point increase in needs met. In the U.S., only 26% of women knew about the OTC pill in 2024, highlighting awareness as a key target for 2025–2027.

Contraceptive Pills Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 7265.25 Million in 2026
Market Size Value By	USD 12946.91 Million by 2035
Growth Rate	CAGR of 6.63% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Oral Contraceptives Contraceptive Injectable By Application : Online Offline
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample